› Forums › General Melanoma Community › Pembrolizumab + Lenvatinib
- This topic has 6 replies, 3 voices, and was last updated 3 years, 7 months ago by Mark_DC.
- Post
-
- September 17, 2020 at 6:47 pm
Dear Fighters,STAGE 4 from Dec-2019. After 10 months of TAF/MEK treatment (Targeted Therapy) with good results, due to some progression in brain, I must to change to Pembro (Immunotherapy). I have a chance to get in clinical trial with Pembio + Lenvatinib. In this trial I have 50% chance of take Lenvatinib drug.
Is there someone participating in this clinical trial? Can you share me your experience?
I just see one post talking about Lenva, published last year.Kind reagards,
JayA
- Replies
-
-
- September 18, 2020 at 9:02 pm
Hi Jay,
I have been on the leap-004 trial of pembro and Lenvatinib for 15 months (definitely on the Lenvatinib). I’ve had some progression that we’ve managed with radiation but generally it has kept things under control. It’s a tough trial though, lots of blood pressure issues, they watch your cardiac status closely, have some neuropathy, currently having some liver enzyme issues. Tired most of the time, nausea for several months now. From what I hear, there are a few on the trial (I’m in Toronto) and sounds like the results are pretty reasonable across the board, but it’s been a tough slog.Hope his helps!
Linda-
- September 19, 2020 at 3:31 am
Dear Jay and Linda, I just found this post tonight on twitter about this trialLBA44 – Lenvatinib+pembro for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004 $MRK #ESMO20
n=103 incl. 28.2% w/ PD on prior aPD-1/L1+aCTLA-4
cORR by BICR 21.4% 2CR/20PR overall
cORR 31.0% in pts w/ PD on prior ICIs pic.twitter.com/5CkRp6CfI4— Bertrand Delsuc (@BertrandBio) September 18, 2020
It posts to a more detailed study with response rates
It seems that they think it makes a difference for those who progressed on anti PD1, they are getting some responses
Hope this helps
Mark -
- September 19, 2020 at 12:28 pm
Thank you Linda and Mark. -
- September 19, 2020 at 7:53 pm
Lenvatinib plus pembrolizumab for advanced #melanoma that progressed on a PD-1 or PD-L1 inhibitor – some hope for pre-treated patients, especially for those treated ipi+nivo before#melsm #ESMO20 @myESMO pic.twitter.com/2xOo9NPKgK
— Pawel Sobczuk (@pawel_sobczuk) September 19, 2020
Jason Luke posted this link on twitter too on study results at ESMO
For me they are too hard to understand – my intuition is that they are seeing some benefits, and that this is a good result given earlier progression on PD1
Probably best to discuss with your oncologist, or for experts here to chip in. Or maybe they will summarize later in an onclive video -
- September 19, 2020 at 7:53 pm
Lenvatinib plus pembrolizumab for advanced #melanoma that progressed on a PD-1 or PD-L1 inhibitor – some hope for pre-treated patients, especially for those treated ipi+nivo before#melsm #ESMO20 @myESMO pic.twitter.com/2xOo9NPKgK
— Pawel Sobczuk (@pawel_sobczuk) September 19, 2020
Jason Luke posted this link on twitter too on study results at ESMO
For me they are too hard to understand – my intuition is that they are seeing some benefits, and that this is a good result given earlier progression on PD1
Probably best to discuss with your oncologist, or for experts here to chip in. Or maybe they will summarize later in an onclive video
-
- You must be logged in to reply to this topic.